Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of the biguanide metformin and the PD-1 inhibitor pembrolizumab. This specific regimen is being evaluated in a Phase 2 clinical trial (NCT04414540) sponsored by Dr. Trisha Wise-Draper at the University of Cincinnati for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Metformin, an established antidiabetic small molecule, is utilized here for its potential to modulate the tumor microenvironment by inhibiting the JAK/STAT3 pathway and CXCL1, thereby enhancing natural killer (NK) cell-mediated cytotoxicity. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), reactivating the T-cell-mediated immune response against tumor cells. The study aims to determine if metformin can synergistically improve the efficacy of pembrolizumab in HNSCC patients.
- Other names
- metformin ER + pembrolizumabmetformin extended release + pembrolizumab
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)PDCD1 (Programmed cell death protein 1 receptor)CXCL1 (C-X-C motif chemokine ligand 1)JAK (Janus kinase family)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on metformin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + pembrolizumab.